<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4822">
  <stage>Registered</stage>
  <submitdate>12/12/2013</submitdate>
  <approvaldate>12/12/2013</approvaldate>
  <nctid>NCT02014116</nctid>
  <trial_identification>
    <studytitle>A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body</studytitle>
    <scientifictitle>A Phase 1 Study of LY3009120 in Patients With Advanced or Metastatic Cancer</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>I6X-MC-JBDA</secondaryid>
    <secondaryid>13873</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Neoplasms</healthcondition>
    <healthcondition>Neoplasm Metastasis</healthcondition>
    <healthcondition>Melanoma</healthcondition>
    <healthcondition>Carcinoma, Non-Small-Cell Lung</healthcondition>
    <healthcondition>Colorectal Neoplasms</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Non small cell</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bowel - Back passage (rectum) or large bowel (colon)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - LY3009120 capsule

Experimental: LY3009120 - LY3009120 in escalating dose cohorts given orally BID (twice daily) every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.


Treatment: drugs: LY3009120 capsule
Administered orally.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Maximum Tolerated Dose (MTD) of LY3009120</outcome>
      <timepoint>Cycle 1 (28 Days)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Participants with Tumor Response</outcome>
      <timepoint>Baseline through study completion (estimated as 37 months)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3009120</outcome>
      <timepoint>Cycle 1: Predose up to 12 hours postdose (Cycle = 28 Days)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics (PK): Area Under the Concentration Curve (AUC) of LY3009120</outcome>
      <timepoint>Cycle 1: Predose up to 12 hours postdose (Cycle = 28 Days)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Advanced or metastatic cancer

          -  Other available therapies have failed to cure the cancer

          -  The cancer that has no proven effective therapy

          -  The cancer can be biopsied (depending on the tumor type and/or the dose of drug
             received, tumor biopsies may be required)

          -  Able to swallow capsules</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Have active cancer in the brain or spinal cord

          -  Have an active infection of any kind (fungal, viral, or bacterial)

          -  Have a cancer of the blood

          -  Are pregnant or breastfeeding

          -  Have some types of eye problems or impairments</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>26/11/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>50</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/05/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Nedlands</hospital>
    <postcode>6009 - Nedlands</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Villejuif</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Eli Lilly and Company</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The main purpose of this study is to see how safe the investigational drug known as LY3009120
      is and whether it will work to help people with advanced cancer or cancer that has spread to
      other parts of the body.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02014116</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Call 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559 Mon-Fri 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST</name>
      <address>Eli Lilly and Company</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>